

# Patterns of triclosan resistance in Vibrionaceae

Keri A Lydon<sup>1</sup>, Megan Robertson<sup>1</sup>, Erin K. Lipp<sup>Corresp. 1</sup>

<sup>1</sup> Environmental Health Science, University of Georgia

Corresponding Author: Erin K. Lipp

Email address: elipp@uga.edu

The antimicrobial additive triclosan has been used in personal care products widely across the globe for decades. Triclosan resistance has been noted among *Vibrio* spp., but reports have been anecdotal and the extent of phenotypic triclosan resistance across the Vibrionaceae family has not been established. Here, triclosan resistance was determined for Vibrionaceae strains across nine distinct clades. Minimum inhibitory concentrations (MIC) were determined for 71 isolates from clinical (n=6) and environmental sources (n=65); only 2 were susceptible to triclosan. The mean MIC for all resistant Vibrionaceae was 53  $\mu\text{g mL}^{-1}$  (range 3.1-550  $\mu\text{g mL}^{-1}$ ), but was significantly different between clades ( $p < 0.001$ ). The highest mean triclosan MIC was observed in the Splendidus clade (200  $\mu\text{g mL}^{-1}$ ; n=3). Triclosan mean MICs were 68.8  $\mu\text{g mL}^{-1}$  in the Damselae clade and 45.3  $\mu\text{g mL}^{-1}$  in the Harveyi clade. The lowest mean MIC was observed in the Cholerae clade with 14.4  $\mu\text{g mL}^{-1}$ , which was primarily represented by clinical strains. There were no significant differences in triclosan MIC among individual species or among environmental strains isolated from different locations. Overall, phenotypic triclosan resistance appears to be widespread across multiple clades of Vibrionaceae.

**Patterns of triclosan resistance in Vibrionaceae**

Keri Ann Lydon<sup>a</sup>, Megan Robertson<sup>a</sup>, and Erin K. Lipp<sup>a#</sup>

Department of Environmental Health Science, University of Georgia, Athens, Georgia, USA<sup>a</sup>

#Address of correspondence to Erin K. Lipp, [elipp@uga.edu](mailto:elipp@uga.edu)

# Abstract

The antimicrobial additive triclosan has been used in personal care products widely across the globe for decades. Triclosan resistance has been noted among *Vibrio* spp., but reports have been anecdotal and the extent of phenotypic triclosan resistance across the Vibrionaceae family has not been established. Here, triclosan resistance was determined for Vibrionaceae strains across nine distinct clades. Minimum inhibitory concentrations (MIC) were determined for 71 isolates from clinical (n=6) and environmental sources (n=65); only 2 were susceptible to triclosan. The mean MIC for all resistant Vibrionaceae was 53  $\mu\text{g mL}^{-1}$  (range 3.1-550  $\mu\text{g mL}^{-1}$ ), but was significantly different between clades ( $p<0.001$ ). The highest mean triclosan MIC was observed in the Splendidus clade (200  $\mu\text{g mL}^{-1}$ ; n=3). Triclosan mean MICs were 68.8  $\mu\text{g mL}^{-1}$  in the Damselae clade and 45.3  $\mu\text{g mL}^{-1}$  in the Harveyi clade. The lowest mean MIC was observed in the Cholerae clade with 14.4  $\mu\text{g mL}^{-1}$ , which was primarily represented by clinical strains. There were no significant differences in triclosan MIC among individual species or among environmental strains isolated from different locations. Overall, phenotypic triclosan resistance appears to be widespread across multiple clades of Vibrionaceae.

# Introduction

The bacterial Family Vibrionaceae is made up of 7 genera and 142 species, grouped into 23 distinct clades (Sawabe, Kita-Tsukamoto & Thompson, 2007; Sawabe et al., 2013). These aquatic bacteria exhibit high amounts of gene exchange (Polz et al., 2006), and act as opportunistic pathogens to both humans and marine organisms. Common pathogenic species in humans include *V. cholerae*, *V. vulnificus*, *V. parahaemolyticus*, *V. alginolyticus*, and *Photobacterium damsela*; however, any member of the Vibrionaceae associated with clinical disease is nationally reportable in the U.S. under the Cholera and Other Vibrio Illness Surveillance (COVIS) program (U.S. Centers for Disease Control and Prevention (CDC), 2017). In some cases, these infections may lead to severe outcomes including fatal bouts of diarrhea due to dehydration or fatal septicemia in patients with compromised immune systems (Hlady and Klontz, 1996; Guerrant, Carneiro & Dillingham, 2003; Menon et al., 2014). Antibiotics are commonly used for treatment, with varying success rates (Wong et al., 2015). The role of antibiotic resistance in these bacteria has been investigated in environmental and retail oysters (Han et al., 2007), with some studies suggesting widespread resistance to multiple antibiotics in some strains of Vibrionaceae from both clinical and environmental origin (Garg et al., 2000; Baker-Austin et al., 2009; Kitaoka et al., 2001).

Although there is a well-established line of research on the role of antibiotic resistance among *Vibrio* spp., there is comparatively little research on resistance to non-therapeutic antimicrobial biocides in personal care products, which are used ubiquitously. One such antimicrobial is triclosan (2,4,4'-trichloro-2'-hydroxydiphenyl ether), for which resistance has been noted in some *Vibrio* spp., including *V. cholerae* (Massengo-Tiasse and Cronan, 2008; DeLorenzo et al., 2016). *V. cholerae* was shown to possess an alternate isoform (FabV) of FabI,

the enoyl-acyl carrier protein reductase that triclosan targets through binding, leading to eventual inhibition of fatty acid synthesis (Levy et al., 1999; Reiss et al., 2002; Massengo-Tiasse and Cronan, 2008). FabV from *V. cholerae* was able to confer resistance to triclosan in *E. coli* clones with the alternate enzyme, with up to 20-fold higher concentrations (up to 10  $\mu\text{g mL}^{-1}$ ) required to inhibit growth (Massengo-Tiasse and Cronan, 2008; Zhu et al., 2010). Other mechanisms of triclosan resistance that may be present include the expression of alternative or mutated enzymes, and/or the presence of efflux pumps, which has been noted in *Pseudomonas aeruginosa*, *E. coli*, and *Salmonella enterica* (Chuanchuen, Karkhoff-Schweizer & Schweizer, 2003; Braudaki and Hilton, 2004; Yazdankah et al., 2006). In fact, triclosan has been demonstrated to both induce antibiotic resistance in biofilms and benthic microbial communities (Nietch et al., 2013; Carey and McNamara, 2015) and confer cross-resistance to other important antimicrobials, as was found in *Salmonella* and *E. coli* (Braudaki and Hilton, 2004). Understanding the extent of triclosan resistance in Vibrionaceae is important given that reported cases have increased by 54% since 2016 (Marder et al., 2018) and have nearly doubled since 1996 in the US (U.S. Center for Disease Control and Prevention, 2016).

Research to date is limited to only a few studies but such evidence suggests that triclosan resistance may be common among *Vibrio* (Massengo-Tiasse and Cronan, 2008; DeLorenzo et al., 2016); however, there has been no attempt to systematically evaluate resistance patterns. Here, we examined triclosan resistance across a range of species and clades within Vibrionaceae, including environmental isolates, to provide a baseline for triclosan resistance in this group.

## Materials and Methods

### *Vibrionaceae* Isolates

Sixteen isolates (13 species representing five clades) were obtained from American Type Culture Collection (ATCC) or courteously provided from the culture collection of Rita Colwell (University of Maryland) (Supplemental Data File 1). Members of clades represented are common human pathogens and include 7 isolates of clinical origin. In addition, 55 presumptive *Vibrionaceae* isolates were collected from coastal surface waters on thiosulfate-citrate-bile salts-sucrose (TCBS) agar plates during a previous study (Lydon et al., 2017). Isolates were obtained from three coastal sites in the southeast U.S. between July and September 2014. Two stations were in the lower Florida Keys, including an offshore site (Looe Key Reef in the Florida Keys National Marine Sanctuary; 24.5449 N 81.40713 W; sampled under permit number FKNMS-2010-131-A1) and an inshore residential canal (Doctors Arm, Big Pine Key, FL; 24.700294 N 81.351825 W). The final station was Clam Bank Landing in North Inlet Estuary (Georgetown, SC; 33.333933 N 79.192913 W). Triclosan concentrations at the time of sampling for these locations were 103, 362, and 18 ng L<sup>-1</sup>, for Looe Key Reef, Doctors Arm Canal, and Clam Bank Landing, respectively (Lydon et al., 2017).

#### *Identification of environmental Vibrionaceae isolates*

Presumptive *Vibrionaceae* isolates were identified by sequencing of the Hsp60 gene (Thompson et al., 2005; Preheim, Timberlake & Polz, 2011; Jesser and Noble, 2018). Pure cultures were extracted by boiling lysis. Extracted DNA was quantified (NanoDrop 1000, Thermo Scientific, Wilmington, DE) and diluted to 5 ng μL<sup>-1</sup> before being subjected to PCR amplification using primers H279 (5'-GAATTCGAIIGCIGGIGA(TC)GGIACIACIAC-3') and H280 (5'-CGCGGGATCC(TC)(TG)I(TC)(TG)ITCICC(AG)AAICCGIGGC(TC)TT-3') (Goh et al., 1996; Kwok et al., 2002; Thompson et al., 2005; Preheim, Timberlake & Polz, 2005). Amplification reactions contained 10 μL of 5x Master Mix (New England BioLabs (NEB),

Ipswich, MA; Final concentration 1x), 0.5  $\mu$ M of each forward and reverse primers, and 10  $\mu$ L of DNA template with molecular grade water for a final volume of 50  $\mu$ L per reaction. PCR conditions on the thermal cycler (T100 Thermal Cycler, BioRad Laboratories Inc.) were 95°C for 3 min for initial denaturation followed by 20 cycles of 30 sec at 95°C, 30 sec at 37°C, 1 min at 72°C. The final extension step was 72°C for 2 min. Amplicons were purified using equal volume SPRI magnetic beads (Sera-Mag SpeedBeads, Thermo Scientific, Freemont, CA) (Rohland and Reich, 2012) with 96 well magnetic plate (Promega MagnaBot II) and stored at -20°C. Samples were sent to the Georgia Genomics and Bioinformatics Core (GGBC) (Athens, GA) and sequenced by Sanger sequencing (Applied Biosystems 3730xl 96-capillary DNA Analyzer).

To determine presumptive Vibrionaceae isolate identity, sequencing reads were loaded into Geneious (version R11) and checked for quality before being subjected to BLAST (Pearson and Lipman, 1988) against the chaperone database (cpnDB) by selecting for non-redundant group I sequences (*hsp60*) (<http://cpndb.ca/>; Accessed May 02, 2018). Subsequently, isolates were classified by clade and presumptive species by their closest cpnDB BLAST match. Isolate sequences were aligned with MUSCLE in Unipro UGENE v.1.26.3 (Edgar et al., 2004; Okonechnikov et al., 2012). The resulting alignment was used to build a phylogenetic tree using PhyML maximum likelihood with aLRT SH-like branch support (Guindon et al., 2010). The resulting tree was visualized using iTOL (version 4.0.3) and used in conjunction with BLAST match to identify closest Vibrionaceae clade (Letunic and Bork, 2007; Fig. 1). All sequences were submitted to NCBI GenBank with the BankIt submission tool (accession nos. MG975785-MG975835). The matching accession no. for each isolate can be found in the supplemental data file.

# 139 *Triclosan MIC screening*

140 All isolates were screened for triclosan minimum inhibitory concentrations (MIC) using  
 141 modified broth microdilution assays (Clinical and Laboratory Standards Institute (CLSI, 2012).  
 142 Isolates were grown overnight at 30°C with shaking (130 rpm; Classic Series C-24 Incubator  
 143 Shaker, New Brunswick Scientific) in 2 mL of ½ strength Marine Broth (Zobell Marine Broth  
 144 2216, HiMedia) + NaCl (Final concentration 0.972%), after which 1 mL of growth was  
 145 transferred to 4 mL of fresh Muller Hinton Broth + NaCl (Final concentration 2%) and continued  
 146 to incubate at 30°C for 4 h (with shaking at 130 rpm) to achieve log phase growth. *E. coli*  
 147 (ATCC 15597) was also screened in the same manner as *Vibrio* isolates, but grown in LB broth  
 148 in place of ½ strength Marine Broth. This isolate served as a triclosan positive control given that  
 149 *E. coli* is susceptible to triclosan (McMurry, Oethinger & Levy, 1998; Lambert and Pearson,  
 150 2000). Cultures were adjusted to 0.5 McFarland Standard in Muller Hinton Broth and exposed to  
 151 eight triclosan concentrations, ranging from 0.78 µg mL<sup>-1</sup> to 100 µg mL<sup>-1</sup> (in two-fold dilutions),  
 152 in duplicate, with a final broth volume of 200 µL. Triclosan working stock (0.8 mg mL<sup>-1</sup>) was  
 153 prepared by dissolving triclosan (Irgasan, ≥97.0% HPLC, Sigma Aldrich) into 100% ethanol  
 154 (Decon Laboratories). The final assay was conducted in UV-sterilized 96-well low binding plates  
 155 (SiliGaurd, Analytical Sales and Services, Inc). In addition to triclosan exposures, each plate  
 156 included two negative controls (sterile Muller Hinton Broth and 10% Ethanol), as well as isolates  
 157 without exposure to triclosan, in duplicate. The plates were placed at 120 rpm in a shaking  
 158 incubator at 30°C and read at 48 h.

159 The lowest triclosan concentration in which there was no bacterial growth was noted as  
 160 the MIC. The MIC concentrations for each replicate exposure were averaged. Those isolates that  
 161 had MICs greater than 100 µg mL<sup>-1</sup> were further screened at higher concentrations by streaking

directly onto Muller Hinton Agar + 2% NaCl agar plates containing final triclosan concentrations of 0, 50, 100, 200, 300, 400, 500, 600, and 700  $\mu\text{g mL}^{-1}$ . All assays were completed in duplicate. Agar plates were used in place of broth due to the hydrophobic properties of triclosan and a tendency for triclosan to precipitate out of solution at higher concentrations.

Classification of susceptible and resistant bacteria by MIC value is normally determined by evaluation of an antibiotic's properties including screening of MICs across a large subset of bacterial types (Sirot, Courvalin & Soussy, 1996). However, triclosan MIC data are limited and to our knowledge there is no published consensus on a cut-off level for resistant or susceptible MIC levels. Thus, we classified triclosan resistance in this study as any isolate exhibiting a triclosan MIC concentration higher than what was observed in our *E. coli* control, or greater than 3.1  $\mu\text{g mL}^{-1}$ .

### *fabV* in Published Vibrionaceae Genomes

To investigate how widespread *fabV* was in published Vibrionaceae genomes, a nucleotide BLAST was conducted against the NCBI complete prokaryote genome database selecting only for those genomes classified as Vibrionaceae (taxid:641).

### Statistical Analyses

Triclosan MIC readings were log-transformed to approximate a normal distribution. Results of the D'Agostino & Pearson normality test indicated that log-transformed data were normally distributed ( $K^2=4.09$ ,  $p=0.1294$ ). Triclosan readings were checked for the assumption of equal variances using the Brown-Forsythe test. Equal variances were found for all comparison types: by species ( $F_{2,27}=0.2743$ ,  $p=0.7622$ ), location ( $F_{2,51}=0.42$ ,  $p=0.6558$ ), and clade ( $F_{3,47}=1.589$ ,  $p=0.2046$ ). Having passed both assumptions of normality and equal variance, log-transformed triclosan MICs were compared using one-way ANOVA to determine differences

amongst species, locations, and clades. For analysis of MIC by species, isolates were included in a species group if their BLAST closest match was greater than 97% identity (Supplementary Data File) and there were more than three isolates available.

## Results

### *Triclosan Minimum Inhibitory Concentrations*

The mean triclosan MIC observed for all Vibrionaceae isolates (n=71) was 53  $\mu\text{g mL}^{-1}$  with a range of 3.1-550  $\mu\text{g mL}^{-1}$ . Over 97% (69/71) of isolates showed phenotypic triclosan resistance ( $>3.25 \mu\text{g mL}^{-1}$ ) (Fig. 2). Only two Vibrionaceae isolates, both of which were collected from environmental sources, were susceptible to triclosan: *Photobacterium* sp. strain CB 6 (Damselae clade) from Clam Bank, SC and *Vibrio* sp. strain DA 5 (Cholerae clade) from Doctors Arm, FL. MICs of  $\leq 100 \mu\text{g mL}^{-1}$  of triclosan was required to inhibit growth for 90% of isolates. There were 11 isolates that exhibited elevated levels of resistance ( $\geq 100 \mu\text{g mL}^{-1}$ ) to triclosan. These isolates belonged to both the *Photobacterium* and *Vibrio* genera and came from all three of our environmental sampling sites. The highest triclosan MIC (550  $\mu\text{g mL}^{-1}$ ) was observed in *Vibrio* sp. strain LK 11 (closest clade was Splendidus; hsp60 sequence 90.30% identity with *Vibrio crassostreae* NZ\_AJZC01000106) isolated from surface water at Looe Key Reef.

Triclosan MICs were compared by clade for those clades that included more than three isolates. Results of one-way ANOVA indicated significant differences in mean triclosan MICs for the Cholerae, Damselae, Harveyi, and Splendidus clades ( $F_{3,47}=4.615$ ,  $p=0.0065$ ). Mean MICs were 14.4  $\mu\text{g mL}^{-1}$ , 68.8  $\mu\text{g mL}^{-1}$ , 45.3  $\mu\text{g mL}^{-1}$ , and 200  $\mu\text{g mL}^{-1}$  for the Cholerae (n=5), Damselae (n=4), Harveyi (n=39), and Splendidus (n=3) clades, respectively (Fig. 3). Post-hoc

multiple comparisons (Tukey's Multiple Comparisons Test) indicated significantly lower triclosan MICs for the Cholerae clade in comparison with Harveyi (adjusted p-value=0.0283) and Splendidus clades (adjusted p-value=0.0149), and Damselae (adjusted p-value=0.0178). Of these clades, Splendidus exhibited the widest range of triclosan MIC readings (25-550  $\mu\text{g mL}^{-1}$ ; n=3) while Cholerae, primarily from clinical sources, showed the smallest range (3.1-18.8  $\mu\text{g mL}^{-1}$ ; n = 6).

When examining environmental isolates based on where they were obtained, there were no significant differences in mean triclosan MICs among the three stations (Fig. 4;  $F_{2,51}=1.346$ , p=0.2694). There were no significant differences in triclosan MICs for environmental Vibrionaceae among presumptive species in the Harveyi Clade (when there were more than three isolates per species; clinical isolates excluded) ( $F_{2,27}=0.2743$ , p=0.7622). Mean triclosan MICs were 54  $\mu\text{g mL}^{-1}$  for *V. alginolyticus* (n=14), 40  $\mu\text{g mL}^{-1}$  for *V. campbellii* (n=5), 37.5  $\mu\text{g mL}^{-1}$  for *V. harveyi* (n=11) (Fig. 5). Of these presumptive species, *V. alginolyticus* exhibited the widest range of triclosan MIC readings (9.4-200  $\mu\text{g mL}^{-1}$ ), while the smallest range was observed in *V. campbellii* (12.5-75  $\mu\text{g mL}^{-1}$ ).

Investigation of *fabV* in whole genome sequences of Vibrionaceae resulted in 119 significant hits for the *fabV* gene within 131 published closed Vibrionaceae genomes. This demonstrated that *fabV* typically occurs in Vibrionaceae but is not universal. In addition, *fabV* appeared to occur on either chromosome I or II, though occurring most frequently on chromosome I.

## Discussion

This study characterized phenotypic triclosan resistance in a wide range of Vibrionaceae isolates through measurement of MICs. Results suggest that members of Vibrionaceae are broadly resistant to triclosan across three genera (*Vibrio*, *Allivibrio*, and *Photobacterium*), nine clades (Cholerae, Coralliilyticus, Damselae, Fischeri, Halioticoli, Harveyi, Orientalis, Splendidus, and Vulnificus), and 15 species (*A. fischeri*, *V. alginolyticus*, *V. brasiliensis*, *V. campbellii*, *V. cholerae*, *V. coralliilyticus*, *V. furnissii*, *V. harveyi*, *V. mimicus*, *V. parahaemolyticus*, *V. pelgaius*, *V. rotiferianus*, *V. splendidus*, *V. vulnificus*, and *P. damsela*). Furthermore, these included known pathogens (e.g., clinical strains from established culture collections), as well as recently collected environmental isolates from distinctly different ecosystems with variable amounts of anthropogenic impacts (Lydon et al., 2017).

Triclosan resistance was previously documented in *V. cholerae* (Massengo-Tiasse and Cronan, 2008) and was suspected in unidentified *Vibrio* spp. from the estuarine environment (DeLorenzo et al., 2016), but resistance had not been systematically examined across a wide range of Vibrionaceae. Moreover, to our knowledge, this is the first study to report phenotypic triclosan resistance in the closely related genus *Photobacterium*, which include species that are both human and fish pathogens (e.g., *P. damsela*) (Rivas, Lemos & Osorio, 2013). We also note that the highest triclosan resistance MIC was observed in a presumptive *V. crassostreae* isolate, an emerging shellfish pathogen (Bruto et al., 2017). Triclosan MICs demonstrated here for Vibrionaceae are consistent with MICs reported for known triclosan resistant bacteria, including *Pseudomonas aeruginosa* and *Staphylococcus aureus* (MICs ranging from 5 to greater than 2,000  $\mu\text{g mL}^{-1}$ ) (Chuanchuen, Karkhoff-Schweizer & Schweizer, 2003; Zhu et al., 2010).

There is growing evidence that *Vibrio* could be enriched in coastal waters by pharmaceutical wastes and antimicrobial agents in personal care products (Peele et al., 1981;

Grimes, Singleton & Colwell, 1984; DeLorenzo et al., 2016; Lydon et al., 2017). Triclosan resistance has specifically been hypothesized as a potential factor leading to increased abundance of *Vibrio* bacteria after exposure of seawater or marine organisms to triclosan (DeLorenzo et al., 2016; Lydon et al., 2017). *V. alginolyticus* demonstrated MICs up to 200  $\mu\text{g mL}^{-1}$  and are an emerging cause of vibriosis cases in the US, with infections increasing by 12-fold from 1996 to 2012, the highest rate of any *Vibrio* (Slifka, Newton & Mahon, 2017). Triclosan has the capacity to induce cross- or multiple- antibiotic resistance (Nietch et al., 2013; Carey and McNamara, 2015); therefore, we suspect there are risks of inducing resistance in the environment as Vibrionaceae have plastic genomes and high gene transfer rates (Polz et al., 2006; Quirke et al., 2006).

We observed significant differences in MIC between *Vibrio* at the Clade level, suggesting that there may be some evolutionary role in resistance; however, much of this difference was driven by low MICs among the Cholerae clade, which was over-represented by clinical strains compared to other clades. Furthermore, differences were not observed between species, which may support the alternate hypothesis that triclosan resistance may be ubiquitous among *Vibrio* but may occur through multiple mechanisms. Triclosan resistance has previously been identified in *V. cholerae* through the expression of a FabI analog, FabV, which prohibits triclosan from binding and interrupting fatty acid synthesis (Massengo-Tiasse and Cronan, 2008). Analysis of published closed whole genome sequences confirmed that *fabV* is highly associated with *Vibrio* spp., including non-cholerae species, but also demonstrated that it is not universal among Vibrionaceae genomes. We suspect the wide variability in triclosan resistance for Vibrionaceae is due to the presence of multiple resistance pathways, including the presence of FabV, overexpression of FabI, and efflux pumps that may be acting singularly or synergistically. These

are particularly important as they could confer resistance to other antibiotics, which could have significance for clinical applications.

## Conclusions

Triclosan resistance appears to be nearly universal across Vibrionaceae isolates tested in this study. Levels of resistance (MICs) were distinguishable between Vibrionaceae clades, suggesting that some level of resistance is dependent on phylogeny, rather than environmental source, which showed no difference in MICs. This work is important in that it provides a broad examination of phenotypic resistance to this persistent antimicrobial compound among this group of potential pathogens. However, future investigations are needed to establish why triclosan resistance is so variable across the Vibrionaceae. We suspect the wide variability is likely due to multiple resistance mechanisms, which could have broader implications for emergence of antibiotic resistance.

**Acknowledgements.** We thank M Ghazaleh Bucher, K Kemp, D Kemp, A Oladeinde, RS Rozier, J Westrich, M Edwards, K Herrington, and K Isaak for their assistance and advice.

## References

Baker-Austin C, McArthur JV, Lindell AH, Wright MS, Tuckfield RC, Gooch J, Warner L, Oliver J, Stepanauskas R. 2009. Multi-site analysis reveals widespread antibiotic resistance in the marine pathogen *Vibrio vulnificus*. *Microbial Ecology* 57:151-159.

297 Braoudaki M, Hilton AC. 2004. Low level of cross-resistance between triclosan and antibiotics  
298 in *Escherichia coli* K-12 and *E. coli* O55 compared to *E. coli* O157. *FEMS Microbiology*  
299 *Letters* 235:305-309.

300 Bruto M, James A, Petton B, Labreuche Y, Chenivresse S, Alunno-Bruscia A, Polz MF, Le Roux  
301 F. 2017. *Vibrio crassostreae*, a benign oyster colonizer turned into a pathogen after plasmid  
302 acquisition. *The ISME J.* 11:1043-1052.

303 Carey DE, McNamara PJ. 2015. The impact of triclosan on the spread of antibiotic resistance in  
304 the environment. *Frontiers in Microbiology* 5.

305 Chuanchuen R, Karkhoff-Schweizer RR, Schweizer HP. 2003. High-level triclosan resistance in  
306 *Pseudomonas aeruginosa* is solely a result of efflux. *American Journal of Infection Control*  
307 31:124-127.

308 CLSI. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow  
309 aerobically. Approved Standard-Ninth Edition. Clinical and Laboratory Standards Institute,  
310 950 West Valley Rd, Ste 2500, Wayne, PA, 19087, USA.

311 DeLorenzo ME, Brooker J, Chung KW, Kelly M, Martinez J, Moore JG, Thomas M. 2016.  
312 Exposure of the grass shrimp, *Palaemonetes pugio*, to antimicrobial compounds affects  
313 associated *Vibrio* bacterial density and development of antibiotic resistance. *Environmental*  
314 *Toxicology* 31:469-477.

315 Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and high  
316 throughput. *Nucleic Acids Research* 32:1792-1797.

317 Garg P, Chakraborty S, Basu I, Datta S, Rajendran K, Bhattacharya T, Yamasaki S, Bhattacharya  
318 SK, Takeda Y, Nair GB, Ramamurthy T. 2000. Expanding multiple antibiotic resistance

319 among clinical strains of *Vibrio cholerae* isolated from 1992-7 in Calcutta, India.  
 320 Epidemiology and Infection 124:393-399.

321 Goh SH, Potter S, Wood JO, Hemmingsen SM, Reynolds RP, Chow AW. 1996. WSP60 gene  
 322 sequences as universal targets for microbial species identification: Studies with coagulase-  
 323 negative staphylococci. Journal of Clinical Microbiology 34:818-823.

324 Grimes DJ, Singleton FL, Colwell RR. 1984. Allogenic succession of marine bacterial  
 325 communities in response to pharmaceutical waste. Journal of Applied Bacteriology 57:247-  
 326 261.

327 Guerrant RL, Carneiro BA, Dillingham RA. 2003. Cholera, diarrhea, and oral rehydration  
 328 therapy: Triumph and indictment. Clinical Infectious Diseases 37:398-405.

329 Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. 2010. New algorithms  
 330 and methods to estimate maximum-likelihood phylogenies: Assessing the performace of  
 331 PhyML 3.0. Systematic Biology 59:307-321.

332 Han F, Walker RD, Janes ME, Prinyawiwatukul W, Ge B. 2007. Antimicrobial susceptibilities of  
 333 vibrio parahaemolyticus and vibrio vulnificus isolates from Louisiana gulf and retail raw  
 334 oysters. Applied and Environmental Microbiology 73:7096-7098.

335 Hlady WG, Klontz KC. 1996. The epidemiology of *Vibrio* infections in Florida, 1981–1993.  
 336 Journal of Infectious Diseases 173:1176-1183.

337 Jesser KJ, Noble RT. 2018. Characterizing the ecology of *Vibrio* in the Neuse River Estuary,  
 338 North Carolina using heat shock protein 60 (hsp60) next-generation amplicon sequencing.  
 339 Appl Environ Microbiol. doi: 10.1128/AEM.00333-18

340 Kearsse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, Buxton S, Cooper A,  
341 Markowitz S, Duran C. 2012. Geneious Basic: an integrated and extendable desktop software  
342 platform for the organization and analysis of sequence data. *Bioinformatics* 28:1647-1649.

343 Kitaoka M, Miyata ST, Unterweger D, Pukatzki S. 2011. Antibiotic resistance mechanisms of  
344 *Vibrio cholerae*. *Journal of Medical Microbiology* 60:397-407.

345 Kwok AYC, Wilson JT, Coulthart M, Ng LK, Mutharia L, Chow AW. 2002. Phylogenetic study  
346 and identification of human pathogenic *Vibrio* species based on partial *hsp60* gene  
347 sequences. *Canadian Journal of Microbiology* 48:903-910.

348 Lambert RJW, Pearson J. 2000. Susceptibility testing: accurate and reproducible minimum  
349 inhibitory concentration (MIC) and non-inhibitory concentration (NIC) values. *Journal of*  
350 *Applied Microbiology* 88:784-790.

351 Letunic I, Bork P. 2007. Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree  
352 display and annotation. *Bioinformatics* 23:127-128.

353 Levy CW, Roujeinikova A, Sedelnikova S, Baker PJ, Stuitje AR, Slabas AR, Rice DW, Rafferty  
354 JB. 1999. Molecular basis of triclosan activity. *Nature* 398:383-384.

355 Lydon KA, Glinski DA, Westrich JR, Henderson WM, Lipp EK. 2017. Effects of triclosan on  
356 bacterial community composition and *Vibrio* populations in natural seawater microcosms.  
357 *Elem Sci Anth* 5.

358 Marder EP, Griffin PM, Cieslak PR, Dunn J, Hurd S, Jervis R, Lathrop S, Muse A, Ryan P,  
359 Smith K, Tobin-D'Angelo M.,2018. Preliminary Incidence and Trends of Infections with  
360 Pathogens Transmitted Commonly Through Food — Foodborne Diseases Active  
361 Surveillance Network, 10 U.S. Sites, 2006–2017. *MMWR Morb Mortal Wkly Rep* 67:324–  
362 328.

363 Massengo-Tiasse RP, Cronan JE. 2008. *Vibrio cholerae* FabV defines a new class of enoyl-acyl  
364 carrier protein reductase. *Journal of Biological Chemistry* 283:1308-1316.

365 McMurry LM, Oethinger M, Levy SB. 1998. Triclosan targets lipid synthesis. *Nature* 394:531-  
366 532.

367 Menon M, Yu P, Iwamoto M, Painter J. 2014. Pre-existing medical conditions associated with  
368 *Vibrio vulnificus* septicemia. *Epidemiology & Infection* 142:878-881.

369 Morgulis A, Coulouris G, Raytselis Y, Madden TL, Agarwala R, Schaffer AA. 2008. Database  
370 indexing for production MegaBLAST searches. *Bioinformatics* 24:1757-1764.

371 Nietch CT, Quinlan EL, Lazorchak JM, Impellitteri CA, Raikow D, Walters D. 2013. Effects of  
372 a chronic lower range of triclosan exposure on a stream mesocosm community.  
373 *Environmental Toxicology and Chemistry* 32:2874-2887.

374 Okonechnikov K, Golosova O, Fursov M, team U. 2012. Unipro UGENE: a unified  
375 bioinformatics toolkit. *Bioinformatics* 28:1166-1167.

376 Peele ER, Singleton FL, Deming JW, Cavari B, Colwell RR. 1981. Effects of pharmaceutical  
377 wastes on microbial populations in surface waters at the Puerto Rico Dump Site in the  
378 Atlantic-Ocean. *Applied and Environmental Microbiology* 41:873-879.

379 Polz MF, Hunt DE, Preheim SP, Weinreich DM. 2006. Patterns and mechanisms of genetic and  
380 phenotypic differentiation in marine microbes. *Philosophical Transactions of the Royal  
381 Society B-Biological Sciences* 361:2009-2021.

382 Preheim SP, Timberlake S, Polz MF. 2011. Merging taxonomy with ecological population  
383 prediction in a case study of Vibrionaceae. *Applied and Environmental Microbiology*  
384 77:7195-7206.

385 Quirke AM, Reen FJ, Claesson MJ, Boyd EF. 2006. Genomic island identification in *Vibrio*  
386 *vulnificus* reveals significant genome plasticity in this human pathogen. *Bioinformatics*  
387 22:905-910.

388 Reiss R, Mackay N, Habig C, Griffin J. 2002. An ecological risk assessment for triclosan in lotic  
389 systems following discharge from wastewater treatment plants in the United States.  
390 *Environmental Toxicology and Chemistry* 21:2483-2492.

391 Rivas AJ, Lemos ML, Osorio CR. 2013. *Photobacterium damsela* subsp *damsela*, a bacterium  
392 pathogenic for marine animals and humans. *Frontiers in Microbiology* 4.

393 Rohland N, Reich D. 2012. Cost-effective, high-throughput DNA sequencing libraries for  
394 multiplexed target capture. *Genome Research* 22:939-946.

395 Sawabe T, Kita-Tsukamoto K, Thompson FL. 2007. Inferring the evolutionary history of vibrios  
396 by means of multilocus sequence analysis. *Journal of Bacteriology* 189:7932-7936.

397 Sawabe T, Ogura Y, Matsumura Y, Feng G, Amin AKMR, Mino S, Nakagawa S, Sawabe T,  
398 Kumar R, Fukui Y, Satomi M, Matsushima R, Thompson FL, Gomez-Gil B, Christen R,  
399 Maruyama F, Kurokawa K, Hayashi T. 2013. Updating the *Vibrio* clades defined by  
400 multilocus sequence phylogeny: proposal of eight new clades, and the description of *Vibrio*  
401 *tritoni* sp nov. *Frontiers in Microbiology* 4.

402 Sirot J, Courvalin P, Soussy CJ. 1996. Definition and determination of in vitro antibiotic  
403 susceptibility breakpoints for bacteria. *Clinical Microbiology and Infection* 2.

404 Slifka KMJ, Newton AE, Mahon BE. 2017. *Vibrio alginolyticus* infections in the USA, 1988-  
405 2012. *Epidemiology and Infection* 145:1491-1499.

406 Thompson JR, Pacocha S, Pharino C, Klepac-Ceraj V, Hunt DE, Benoit J, Sarma-Rupavtarm R,  
 407 Distel DL, Polz MF. 2005. Genotypic diversity within a natural coastal bacterioplankton  
 408 population. *Science* 307:1311-1313.

409 U.S. Centers for Disease Control and Prevention. 2017. Cholera and Other *Vibrio* Illness  
 410 Surveillance (COVIS). CDC, Atlanta GA.

411 U.S. Center for Disease Control and Prevention (CDC). National Surveillance of Bacterial  
 412 Foodborne Illnesses (Enteric Diseases): National Cholera and Vibriosis Surveillance. 2016.  
 413 Retrieved from the Center for Disease Control website (Accessed May 08, 2018):  
 414 <https://www.cdc.gov/vibrio/surveillance.html>

415 Wong KC, Brown AM, Luscombe GM, Wong SJ, Mendis K. 2015. Antibiotic use for *Vibrio*  
 416 infections: important insights from surveillance data. *BMC Infectious Diseases* 15.


417 Yazdankhah SP, Scheie AA, Hoiby EA, Lunestad BT, Heir E, Fotland TO, Naterstad K, Kruse  
 418 H. 2006. Triclosan and antimicrobial resistance in bacteria: An overview. *Microbial Drug*  
 419 *Resistance-Mechanisms Epidemiology and Disease* 12:83-90.

420 Zhu L, Lin JS, Ma JC, Cronan JE, Wang HH. 2010. Triclosan Resistance of *Pseudomonas*  
 421 *aeruginosa* PAO1 Is Due to FabV, a Triclosan-Resistant Enoyl-Acyl Carrier Protein  
 422 Reductase. *Antimicrobial Agents and Chemotherapy* 54:689-698.

# **Figure 1**(on next page)

Phylogenetic tree of *hsp60*sequences of presumptive Vibrionaceaeisolates

Vibrionaceae with previously published *hsp60*sequences (cpnDB; <http://cpndb.ca/>; Accessed May 02, 2018)are indicated by their genus and specific epithet (Accession Numbers Listed in Supplemental Data File 1). Branch thickness corresponds to aLRT SH-like branch support (thick line  $\geq 0.5$  (most support), intermediate line = 0.5, and thin line  $\leq 0.5$  (least support)) (Guindon et al., 2010).




## Figure 2 (on next page)

Box and whisker plot of triclosan MICs for Vibrionaceae isolates (n=72)

Whiskers indicate 10-90<sup>th</sup> percentile. *E. coli* was used as the control with an observed MIC of 3.1 µg mL<sup>-1</sup>.


*Vibrionaceae*



# **Figure 3**(on next page)

Triclosan MIC by clade, where there were greater than 3 isolates per clade


Results of one-way ANOVA demonstrated significant differences in mean rank triclosan MICs for isolates by clade ( $F_{3,47}=4.615$ ,  $p=0.0178$ ). Tukey's post-hoc multiple comparisons tests indicated the Cholerae clade had significantly lower triclosan MICs than the Damselae (adjusted p-value=0.0178), Splendidus (adjusted p-value=0.0149), and Harveyi (adjusted p-value=0.0283) clades.



# **Figure 4**(on next page)

Triclosan MIC by location sampled (Doctors Arm, Looe Key, and Clambank Landing)

Results of one-way ANOVA showed no significant differences in triclosan MICs for *Vibrionaceae* by location sampled ( $F_{2,51}=1.346$ ,  $p=0.2694$ ). .



# **Figure 5**(on next page)

Triclosan MIC by species within the Harveyi clade where there were greater than 3 isolates per species tested

Results of one-way ANOVA showed no significant differences ( $p > 0.05$ ) in triclosan MICs among these species ( $F_{2,27} = 0.2448$ ,  $p = 0.7846$ ).

